FDA central documents room
Executive Summary
Rockville, MD-based firm Maxima will operate the FDA's NDA and IND receiving room effective March 31. FDA noted that this is the first time a contractor has handled the documents room. Maxima will be responsible for checking the completeness of applications, accessing drug master files, and forwarding the applications to appropriate agency officials. There is no change in NDA/IND submission procedures.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.